BIOLASE Adds Two New Independent Directors to Its Board

BIOLASE Adds Two New Independent Directors to Its Board 
Finance and Accounting Executive James R. Talevich and Professor
Samuel B. Low of University of Florida's Department of Periodontology
Join Board of Directors 
IRVINE, CA -- (Marketwired) -- 12/11/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, and a pioneer in laser surgery in other medical specialties,
today announced that the Board of Directors (the "Board") has
appointed James R. Talevich and Samuel B. Low, D.D.S., to the Board.
Mr. Talevich and Dr. Low were appointed to the Audit Committee and
Mr. Talevich was appointed Chairman of the Audit Committee. Gregory
Lichtwardt and Erin Enright tendered their resignations from the
Board on December 4, 2013. As a result of these appointments and
resignations, BIOLASE's Board currently consists of six directors,
four of whom are independent directors.  
James R. Talevich has more than 23 years of experience as a senior
financial executive, and is currently a director of Nova LifeStyle,
Inc. (PINKSHEETS: STVS), an international manufacturing company,
where he Chairs the Audit Committee and also serves on the
Compensation and Nominating and Corporate Governance Committees. Mr.
Talevich currently serves as a member of the Executive Committee and
Advisory Council of the SEC Financial Reporting Institute at the USC
Marshall School of Business, and as a member of the UCLA Anderson
School of Management Alumni Board of Directors. He is also a member
of the Concordia University Healthcare Management Advisory Board.  
Mr. Talevich said, "BIOLASE has in place all of the elements
necessary for great market success and a significant increase in
shareholder value. BIOLASE has innovative products, patented
technologies with widespread applicability, and large potential
markets, as well as a talented management team and I look forward to
the opportunity to contribute to its future success."
 Prior to his
current roles, Mr. Talevich served as Chief Financial Officer of
I-Flow Corporation, a NASDAQ-listed medical technology company, from
2000 to 2009, Chief Financial Officer of Tectrix Fitness Equipment
Inc. from 2005 to 2009, and Chief Financial Officer of Gish
Biomedical, Inc., a NASDAQ-listed manufacturing company, from 1999 to
2000. From 2008 to 2009, he served on the Board of Directors of
AcryMed, Inc., a developer of antimicrobial nanoparticle
technologies. Mr. Talevich previously held financial and accounting
positions with Mallinckrodt Group Inc., Sorin Biomedical (Fiat
S.p.A.), Pfizer Inc., SensorMedics Corporation, Baxter International
Inc., and KPMG.  
Mr. Talevich received a B.A. in physics from California State
University, Fullerton, and an MBA from the UCLA Anderson School of
Management. He is licensed as a Certified Public Accountant and is a
member of the Forum for Corporate Directors, Financial Executives
International, OCTANe, DeviceAlliance, and the California Society of
"Jim Talevich brings to BIOLASE a powerful skill set that will serve
our shareholders well in the coming years" said Federico Pignatelli,
Chairman and Chief Executive Officer. "BIOLASE is poised to expand
its business far beyond its current core base in dentistry, and that
will require the depth of knowledge and breadth of experience in
finance, compliance, governance and restructuring that he possesses." 
Samuel B. Low, D.D.S. is Professor Emeritus of the Department of
Periodontology at the University of Florida's College of Dentistry,
where he has spent his entire academic career. Previously he served
as Associate Dean for Continuing Education and Partnerships and
Associate Dean for Administrative Affairs. Dr. Low also maintains an
intramural practice, which includes periodontal dentistry and
Dr. Low said, "I look forward to assisting BIOLASE in achieving its
goals. Technology is the core value for the present and future of
health care, and BIOLASE is in the unique visionary position to be at
the forefront as the total dental technology provider. BIOLASE's
revolutionary lasers are the central focus in managing my patients
and I have been a proud user of WaterLase laser systems in my
practice for the past nine years. WaterLase technology is truly a
game-changer in surgery and the most versatile solution in providing
quality dental care." 
Dr. Low has served on the American Dental Association's Board of
Trustees, as President of the Florida Dental Association and as a
member of the American Academy of Periodontology. He has been on the
editorial board of two academic journals related to dentistry.  
Dr. Low received a B.S. from Lamar University and a D.D.S. from the
University of Texas.  
"Dr. Low is a very accomplished dental professional who has shaped
the professional careers of literally thousands of dentists. He is a
welcome addition to our Board, and we anticipate relying on his depth
of expertise and knowledge to accelerate our growth in our core
dental business in the coming years. We expect both Jim and Sam to be
at the heart of the promising future that lies ahead for BIOLASE,"
concluded Pignatelli. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners and
in-office milling machines; products that are focused on technologies
that advance the practice of dentistry and medicine. The Company's
proprietary laser products incorporate approximately 300 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its innovative products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are revolutionary dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications, and a full line of dental
imaging equipment. BIOLASE has sold more than 24,000 lasers. Other
laser products under development address ophthalmology and other
medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Google+ at, Instagram at and YouTube at  
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
For further information, please contact: 
Michael Porter
Porter, LeVay & Rose, Inc. 
Press spacebar to pause and continue. Press esc to stop.